Literature DB >> 6456809

Parenteral diphosphonates for treating malignant hypercalcemia.

A Jung, C van Ouwenaller, A Chantraine, B Courvoisier.   

Abstract

Two diphosphonates, EHDP (disodium etidronate, or ethanehydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in six patients with one or multiple episodes of malignant hypercalcemia. All patients responded well to the drugs after a delay period of two to seven days. The tolerance of the drugs was excellent. EHDP, and especially Cl2MDP, are promising agents for treating hypercalcemia and inhibiting bone resorption in malignant disorders.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6456809     DOI： 10.1002/1097-0142(19811015)48:8<1922::aid-cncr2820480833>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  4 in total

1.  Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas.

Authors:  H A Kulenkampff; T Dreyer; W Kersjes; G Delling
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study.

Authors:  P M Hyvönen; M J Kowolik
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

3.  Treatment of malignant hypercalcaemia with clodronate.

Authors:  R C Percival; A D Paterson; A J Yates; D J Beard; D L Douglas; F E Neal; R G Russell; J A Kanis
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640

4.  Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.

Authors:  D J Dodwell; A Howell; J Ford
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.